Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 26,200 shares, an increase of 37.2% from the February 13th total of 19,100 shares. Based on an average daily trading volume, of 53,400 shares, the days-to-cover ratio is presently 0.5 days.
Analyst Upgrades and Downgrades
Separately, Raymond James reiterated a “strong-buy” rating on shares of Medexus Pharmaceuticals in a research note on Monday, February 3rd.
Get Our Latest Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Trading Down 1.1 %
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Stories
- Five stocks we like better than Medexus Pharmaceuticals
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- How to Build the Ultimate Everything ETF Portfolio
- Election Stocks: How Elections Affect the Stock Market
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to find penny stocks to invest and tradeĀ
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.